Usefulness of osteoprotegerin in assessing responses to neridronate treatment in Paget's disease of bone

被引:1
|
作者
Ulivieri, F. M. [1 ]
Piodi, L. P. [2 ]
Marotta, G. [1 ]
Marchelli, D. [1 ]
Corradini, C. [3 ]
Parravicini, L. [3 ]
Verdoia, C. [3 ]
Gerundini, P. [1 ]
机构
[1] Osped Maggiore Fdn IRCCS Padiglione Granelli, Dept Nucl Med, Via F Sforza 35, Milan, Italy
[2] Osped Maggiore Fdn IRCCS, Dept Gastroenterol, Milan, Italy
[3] Univ Milan, G Pini Hosp, Dept Orthopaed & Traumatol, Milan, Italy
关键词
Bone metabolism; Neridronate; Osteoprotegerin; Paget's disease of bone;
D O I
10.1007/s10195-006-0147-4
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Osteoprotegerin (OPG) is a protein that inhibits of osteoclastogenesis. The aim this study was to evaluate the response of serum OPG levels to neridronate treatment in patients with Paget's disease of bone resistant to previous therapy. Nine patients (4 men) affected by active Paget's disease of bone (6 polyostotic, 3 monostotic) not responsive to clodronate were studied. Serum OPG, osteocalcin, total and bone isoenzyme of alkaline phosphatase (AP and BAP, respectively), and urinary deoxypyridinoline (DPD) were measured before and 5 months after neridronate treatment (100 mg/day, i.v. for two days). A scintigraphic activity index (SAI) was also calculated before treatment. Mean baseline OPG levels were within normal values and were not significantly different 5 months after neridronate treatment. In contrast, there were significant reductions in AP (41.9%, p<0.02) and BAP (38.8%, p<0.04). Serum OPG levels correlated with DPD (r=0.925) and SAI (r=0.689). Although OPG is an important regulator of bone metabolism, in our series of already treated patients it was not a sensitive marker for diagnosing Paget's disease and for monitoring the response to pharmacological treatment, whereas AP and BAP confirmed their clinical usefulness. This preliminary study requires confirmation by a study with a larger population.
引用
收藏
页码:192 / 194
页数:3
相关论文
共 50 条
  • [31] Paget's disease of bone: Complications and treatment
    Alexandre, C
    REVUE DU RHUMATISME, 1997, 64 (06): : S99 - S102
  • [32] Surgical treatment in Paget's disease of bone
    Kurth, A. A.
    OSTEOLOGIE, 2011, 20 (02) : 138 - 142
  • [33] Diagnosis and treatment of Paget's disease of bone
    Josse, Robert G.
    Hanley, David A.
    Kendler, David
    Ste Marie, Louis-Georges
    Adachi, Jonathan D.
    Brown, Jacques
    CLINICAL AND INVESTIGATIVE MEDICINE, 2007, 30 (05): : E210 - E223
  • [34] Advances in the treatment of Paget's bone disease
    Weinstein, RS
    HOSPITAL PRACTICE, 1997, 32 (03): : 63 - &
  • [35] Short-term intravenous therapy with Neridronate in Paget's disease
    Adami, S
    Bevilacqua, A
    Broggini, M
    Filipponi, P
    Ortolani, S
    Palummeri, E
    Ulivieri, F
    Nannipieri, F
    Braga, V
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2002, 20 (01) : 55 - 58
  • [36] Osteoprotegerin deficiency and juvenile Paget's disease.
    Hofbauer, LC
    Schoppet, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (20): : 1622 - 1622
  • [37] Paget's disease of bone: diagnosis and treatment update
    Noor M.
    Shoback D.
    Current Rheumatology Reports, 2000, 2 (1) : 67 - 73
  • [38] Current Treatment Approaches for Paget's Disease of Bone
    Brandi, Maria Luisa
    DISCOVERY MEDICINE, 2010, 10 (52) : 209 - 212
  • [39] Current options for the treatment of Paget's disease of bone
    Audran, M
    PRESSE MEDICALE, 1996, 25 (29): : 1317 - 1319
  • [40] Intravenous clodronate as treatment for Paget's disease of bone
    Ooi, CG
    Fraser, WD
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 (11) : P44 - P44